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Alcoholism is a chronic and recurrent disease. The studies on ethyl alcohol show a progressive deterioration of cognitive functions 
(motor hyperactivity, operating memory). The aim of the study was to establish whether combined single and chronic administration 
of aripiprazole (ARI) and fluoxetine (FLU) affects animal locomotor activity or modifies spatial memory functions in female rats exposed 
to ethyl alcohol. Female Wistar rats were studied in the Morris Water Maze (MWM) and locomotor activity test. Rats undergoing the 
MWM and locomotor activity test were injected with saline on day 1, 7, 14 and 21 of testing. Results showed a statistically significant 
mobility increase in the group of ethanol‑exposed females (CEt) (21 days) compared to the non‑ethanol‑exposed group (CNEt). Upon ARI 
administration to CEt, no statistically significant differences in animal mobility were found, either upon single or chronic administration. 
Chronic administration of FLU (21 days) as well as combined administration of ARI+FLU (14 and 21 days) caused a statistically significant 
reduction of the females’ mobility compared to the control CEt group. Single and chronic administration of ARI (7x) both show a spatial 
memory improvement in CEt. No memory improvement was observed, however, after 14 and 21  days of ARI administration. FLU, 
likewise, improved spatial memory both upon single and chronic administration. Combined administration of ARI+FLU improved 
memory in CEt only upon single administration. Lack of effect upon chronic administration may be due to tolerance to memory 
improvement developing upon combined administration of ARI+FLU. It can be concluded that ARI (1.5  mg/kg), FLU (5  mg/kg), and 
combined administration of these drugs improves spatial memory in CEt.
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INTRODUCTION
Excessive consumption of ethyl alcohol leads to 
development of an addiction and impairs emotional 
processes and motivational behaviors of the drinker. 
Ethyl alcohol addiction is a set of mental and somatic 
disorders with alternate periods of exacerbation (binge 
drinking) and remission (abstinence). Ethanol withdrawal 
entails numerous mental complaints (anxiety, depression) 
and psychomotor complaints (e.g. motor hyperactivity) 
(Allsop et al. 1997). Neuropsychological studies on patients 
addicted to ethyl alcohol show a progressive deterioration 
of cognitive functions, mainly operating memory 
and executive functions (Guerrini et al. 2005). These 
impairments are probably related to enhanced transmission 
in the dopaminergic system (DA) (Diana et al. 2003). Some 
atypical antipsychotics (olanzapine, quetiapine) have been 
shown to reduce ethyl alcohol consumption in humans; 
however, due to their adverse effects (body weight gain, 
sedation), their use is limited (Zając et al. 2006). 
Aripiprazole (ARI) is a new atypical antipsychotic 
agent with a unique mechanism of action and few adverse 
effects (Zając et al. 2006, Marcus et al. 2008). Its mechanism 
of action is related to its agonist‑antagonist effect on DA 
receptors (D2 and D4) and warrants the use of this drug to 
treat ethyl alcohol addiction (Ratajczak et al. 2013). 
Fluoxetine (FLU) is an antidepressant being a selective 
serotonin reuptake inhibitor (SSRI) used to treat major 
depressive disorders (MDDs) (Holladay et al. 1998). 
Fluoxetine has been shown to have neuroprotective 
properties and to improve cognitive functions – memory 
in particular – in both animals (Li et al. 2009, Malinowska 
et al. 2016) and humans (Gudayol‑Ferré et al. 2015) and, 
thus, may be used to treat memory disorders in alcohol 
addicts (Szymańska et al. 2009). Memory improvement 
was also observed in animals exposed to ethyl alcohol 
(Szymańska et al. 2009, Ratajczak et al. 2015). 
Women have been proved to be more prone to organ 
damage due to alcohol abuse (Tuyns and Pequignot 1984, 
Gavaler and Arria 1995). Alcohol in women is metabolized 
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differently than in men; for instance, with the same amount 
of alcohol consumed women will have a higher blood 
alcohol concentration than the opposite sex (Frezza et al. 
1990, Taylor et al. 1996). Alcohol is metabolized mainly in 
the liver by P‑450 cytochrome (CYP2E1) (Lieber 1999, 2004). 
Alcohol damages liver in women more frequently due to 
the greater volume of liver tissue per dry matter weight 
unit (Li et al. 1998, Kwo et al. 1998). Alcohol absorption 
in women is enhanced by estrogens – this is why women 
get drunk more easily in the premenstrual phase. Higher 
blood alcohol concentration in women may be due to lower 
activity of alcohol dehydrogenase (ADH) in the stomach 
and the liver (National Institute on Alcohol Abuse and 
Alcoholism – NIAAA 1990). Women have also been found 
to experience alcohol‑related brain damage (Hommer et al. 
1996) corresponding to memory impairment.
Therapeutic effect of the drugs used depends on 
pharmacokinetic parameters (LADME) which vary between 
ages, sexes, or drug doses used (Beirle et al. 1999, Koren 
2012). In the absorption phase, differences were observed in 
release of the medicinal substance due to smaller secretion 
of gastric acid in women caused by the predominantly 
alkaline environment (Beirle et al. 1999, Robinson 2002). 
This may result in slower absorption and reduced Cmax 
(Robinson 2002), in particular in women (regardless of the 
menstrual cycle phase) (Wilson 1984). Women also show 
a weaker first pass effect caused by increased CYP2D6 
isoenzyme expression (Luzier et al. 1999). 
Our previous studies on male rats have shown no 
effect of ARI in higher doses (6 mg/kg) on memory of 
alcohol‑exposed rats and memory impairment upon 
combined administration of ARI (6 mg/kg) and FLU 
(5 mg/kg) (Burda‑Malarz et al. 2014a, 2014b).
Considering the fact that the available references lack 
any data on combined administration of ARI and FLU 
on cognitive functions in ethyl alcohol abusing women, 
our study objective was to determine whether combined 
single and chronic administration of aripiprazole (ARI) 
and fluoxetine (FLU) affected animal locomotor activity or 
modified spatial memory functions in female rats exposed 
to ethyl alcohol. 
MATERIALS AND METHODS
Animals
Timed female Wistar rats (100) were purchased 
from Poznan University of Medical Sciences, Poland 
(licensed by Ministry of Agriculture in Warszawa, 
Poland). The animals were housed individually in 
cages (size 42×26 cm) in a light‑controlled (lights on 
7 a.m.–7 p.m.), temperature‑controlled (18–20°C), and 
humidity‑controlled (50–60%) animal facility. The animals 
had free access to rat chow (Labofeed B) and water. All 
females used in our experiment were from litters dropped 
over 2 days’ time (hormonally homogenous group, with an 
average reproductive cycle duration of 4–6 days). 
All procedures related to the use of rats in these 
experiments were conducted with due respect to ethical 
principles regarding experiments on animals (directive 
2010/63/EU). The study protocol was approved by the 
Local Ethics Committee for Research on Animals. 
Drugs
Aripiprazole ARI – Otsuka Pharmaceutical Europe, 
Bristol‑Myers Squibb Poland. 
Fluoxetine FLU – Polpharma SA, Poland. 
Saline – Sodium chloride (0.9%) solution was acquired 
from Baxter Poland Company (Warsaw, Poland). 
The female rats were administered ARI (1.5 mg/kg) 
ip 30 min before the test and FLU (5 mg/kg) po 60 min 
before the test and for 7, 14, and 21 days. ARI and FLU 
were prepared in saline. Between the tests with different 
assays, there was a 24 h washout period to wash out the 
drug residues or their active metabolites. The controls 
were given saline only (2 ml, ip saline) according to the 
same schedule. Separate groups of animals were used for 
different tests.
Behavioral analyses
Ethanol administration (EA)
Animals (n=80) were forced to drink only ethyl alcohol 
solution (12% solution made of 95% stock ethanol; Polmos, 
Poland) for 2 months (~9 g/kg/day). During the next 
4 weeks, the animals were presented with a free choice 
paradigm between tap water and ethyl alcohol. This 
procedure led to preparation of rats chronically exposed 
to alcohol. Additionally, for comparative purposes, 
throughout the duration of chronic ethyl alcohol 
treatment (rats chronically exposed to alcohol), an ethyl 
alcohol‑naive control group of animals would receive only 
tap water (Okulicz‑Kozaryn et al. 2004). Ethyl alcohol was 
the treatment continued throughout the testing period. 
Measurement of locomotor activity (LA)
LA was measured in rats (Control Non‑Ethanol – 
CNEt and Control Ethanol – CEt – groups) using eight 
20.5×28×21 cm wire grid cages, each with two horizontal 
infrared photocell beams along the long axis, 3 cm above 
the floor. Photocell interruptions were recorded by 
electromechanical counters in an adjacent room. Before the 
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test, all groups of animals were habituated to a novel cage 
for 30 min. Rats were also treated with 1.5 mg/kg ARI (ip), 
5 mg/kg FLU (po), or saline in CNEt and CEt study groups. 
Then, photocell activity would be recorded at 5‑minute 
intervals. This test provided an index of basal locomotor 
activity of animals in a familiar environment, necessary 
to indicate the presence of a central stimulant or sedating 
effects of the drug used in the test.
Morris water maze test (MWM)
Morris water maze test (Morris et al. 1988). The water 
maze apparatus was a circular basin (diameter=180 cm, 
height=50 cm) filled with water (approximately 22–24°C) 
to a depth of 24c m, and pieces of Styrofoam were hiding 
an escape platform (diameter=8 cm) placed 1 cm below 
the water surface (learning place, invisible condition). 
Many extra‑maze visual cues surrounding the maze were 
available, and the observer remained in the same location 
for each trial. The rats from the CONTROL CNEt and CEt, 
ARI, FLU, and ARI+FLU groups were placed in the water 
facing the midpoint section of the wall at one of 4 equally 
spaced locations: North (N), East (E), South (S), and West 
(W). The pool was divided into 4 quadrants: NW, NE, SE and 
SW. The rats were allowed to swim freely until they found 
and climbed onto the platform. If a rat failed to locate the 
platform within 60 s, it would be placed on the platform 
for 5 s. Each rat was submitted to 6 trials per day, and the 
starting position was changed at each trial (starting on 
the N side, followed by E, S, W sides, in that order). The 
interval was 5 min between trials 1–3 and 4–6, and 10 min 
between trials 3 and 4. For the first 3 days of maze testing, 
the submerged platform was placed in the NW quadrant. 
The platform was subsequently placed in the SE quadrant 
for the following 3 days. On day 7, the platform was lifted 
above the water level and placed in the SW quadrant, and 
rats were injected saline 30 min before the test (day 1, 7, 
14, and 21 of the experiment). Each rat was subjected to 
a one probe trial consisting of 6 individual trials. The total 
number of times each rat crossed the probe target area 
and the time of the probe trial swim were recorded by the 
observer. The time of each of the 6 trials was noted, and 
a mean value for each rat was calculated (number of escape 
latencies). Moreover, the total number of times each rat 
crossed the area of quadrant – NW, NE, SE, and SW – (crossed 
quadrants) was recorded by the observer and a mean value 
for each rat was calculated (crossed quadrants). The same 
procedures were followed until day 21 of the experiment. 
Statistical analysis
The data are shown as mean values ±SEM. The data 
distribution pattern was not normal (unlike Gaussian 
function). Statistical analyses for spatial memory test 
and LA test were carried out using the non‑parametric 
Kruskal‑Wallis test for unpaired data and ANOVA 
Table I. Effects of single and chronic treatment with ARI and FLU and combined treatment with both drugs on locomotor activity in alcohol‑exposed 
female rats
Group
Activity counts / mean
Friedman  
H[3.39]Single administration
(x±SEM)
Chronic treatment
7 days
(x±SEM)
14 days
(x±SEM)
21 days
(x±SEM)
Saline (0.5 ml/rat)  
CONTROL NON‑ETHANOL 
(CNEt)
71.17±6.04 68.17±6.24 84.33±4.63 74.17±8.75 2.4
Saline (0.5 ml/rat)  
CONTROL ETHANOL  
(CEt)
82.83±4.25
NS vs. CNEt
85.83±6.30
NS vs. CNEt
92.00±3.42
NS NS vs. CNEt
104.50±9.35#
p=0.0293 2.9
ARI 1.5 mg/kg ip  
30 min before the test  
(CEt)
89.33±6.30
NS
74.50±8.89
NS
102.00±7.17
NS
98.67±8.27
NS 3.2
FLU 5 mg/kg po  
60 min before the test  
(CEt)
90.33±5.40
NS
80.50±7.68
NS
100.33±12.13
NS
77.17±8.07*
p=0.0401 3.7
ARI 1.5 mg/kg+FLU  
5 mg/kg (CEt)
86.90±4.09
NS
95.10±5.99
NS
71.90±5.41*
p=0.0057
67.50±5.67*
p=0.0033 5.9
Kruskal‑Wallis H [4.49] 1.9 2.1 8.5 10.4
Number of housed animals=10
* Statistically significant difference p<0.05 vs. CEt group
# Statistically significant difference p<0.05 vs. CNEt group
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Friedman two‑way variance analysis for paired data. 
Statistical significance was tested using Dunn’s and 
Dunnet’s post‑hoc test. 
RESULTS
Effects of single and chronic treatment with ARI 
and FLU and combined treatment with both 
drugs on locomotor activity in alcohol‑exposed 
female rats
There was no statistically significant difference in the 
activity counts between the CEt and CNEt group of rats 
(Table I) either in single or in chronic treatment (7 and 
14 days). Only after 21 days of treatment, a statistically 
significant increase of locomotor activity between CEt and 
CNEt group of rats would be observed (p<0.05 vs. CNEt) 
(Table I). 
ARI at the dose of 1.5 mg/kg in single and chronic 
treatment did not lead to locomotor activity change 
compared to CEt and CNEt control groups of rats 
(Table I). 
FLU at the dose of 5 mg/kg would show a statistically 
significant decrease in the locomotor activity compared 
to the CEt control group of rats (p<0.05 vs. CEt) (Table I) 
only after 21 days of treatment. There was no statistically 
significant difference compared to CNEt control group. 
After chronic treatment (14 and 21 days) with both 
drugs (ARI 1.5 mg/kg and FLU 5 mg/kg), a statistically 
significant decrease in the locomotor activity compared to 
CEt control group (p<0.05 vs. CEt) (Table I) was observed. 
There was no statistically significant difference compared 
to CNEt control group. 
Effects of single and chronic treatment with ARI 
andFLU and combined treatment with both drugs 
on memory measured in the MWM test (escape 
latency) in alcohol‑exposed female rats
There was no statistically significant difference in the 
number of escape latencies between CEt and CNEt group of 
rats (Table II). 
Single and chronic treatment (7 days) with ARI 
(1.5 mg/kg) administered to alcohol‑exposed animals 
showed a statistically significant improvement of spatial 
memory (decrease in the number of escape latencies) 
compared to CEt control group of rats (p<0.05 vs. CEt) 
(Table II). No statistically significant change in the number 
of escape latencies after ARI administration was observed in 
comparison to CNEt and CEt control group of rats (Table II).
Single and chronic administration of FLU (5 mg/kg) 
(7‑ and 14‑days treatment) in alcohol‑exposed female rats 
showed a statistically significant decrease in the number 
of escape latencies compared to CEt control group of rats 
Table II. Effects of single and chronic treatment with ARI andFLU and combined treatment with both drugs on memory measured in the MWM test 
(escape latency) in alcohol‑exposed female rats
Group
Escape latency [s]
Friedman H[3.39]Single 
administration
(x±SEM)
Chronic treatment
7 days
(x±SEM)
14 days
(x±SEM)
21 days
(x±SEM)
Saline (0.5 ml/rat)  
CONTROL NON‑ETHANOL 
(CNEt)
16.32±4.67 11.88±1.52 11.54±2.16 9.58±1.63 7.2
Saline (0.5 ml/rat)  
CONTROL ETHANOL  
(CEt)
21.38±2.32
NS vs. CNEt
17.92±2.21
NS vs. CNEt
12.60±1.38
NS vs. CNEt
11.71±1.39
NS vs. CNEt 8.4
ARI 1.5 mg/kg ip  
30 min before the test  
(CEt)
11.10±1.64*
p=0.0020
11.82±1.63*
p=0.0394
12.30±2.11
NS
9.24±1.09
NS 2.5
FLU 5 mg/kg po  
60 min before the test  
(CEt)
14.65±2.16*
p=0.0479
11.26±1.27*
p=0.0176
8.82±1.12*
p=0.0475
11.79±1.80
NS 4.2
ARI 1.5 mg/kg+FLU  
5 mg/kg (CEt)
13.50±1.85*
p=0.0161
14.24±1.75
NS
14.30±2.29x
p=0.0454
13.87±1.80+
p=0.0411 2.1
Kruskal‑Wallis H [4.49] 10.5 12.4 9.8 7.7
Number of housed animals=10
* Statistically significant difference p<0.05 vs. CEt group
x Statistically significant difference p<0.05 vs. FLU group
+ Statistically significant difference p<0.05 vs. ARI group
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(p<0.05 vs. CEt) which proves spatial memory improvement. 
The memory‑improving effect was not observed after 
21 days of FLU administration compared to CEt control 
group of rats (Table II). There was no statistically significant 
difference compared to CNEt control group (Table II). 
Single administration of ARI+FLU to alcohol‑exposed 
female group of rats was sufficient to cause a statistically 
significant decrease in the number of escape latencies 
compared to CEt group of rats (p<0.05 vs. CEt group) which 
indicates a spatial memory improvement in these groups 
of rats (Table II). There was no statistically significant 
difference compared to CNEt control group (Table II). In 
addition to this, only after chronic treatment with both drugs 
(ARI+FLU) there was a statistically significant deterioration 
in spatial memory compared to 14 days of FLU treatment 
(p<0.05 vs. FLU) and 21 days of ARI treatment (p<0.05 vs. ARI) 
(Table II). There was no statistically significant difference 
following combined treatment with both drugs (ARI+FLU) 
compared to CNEt control group of rats (Table II). 
Effects of single and chronic treatment with ARI 
andFLU and combined treatment with both drugs 
on memory measured in the MWM test (crossed 
quadrants) in alcohol‑exposed female rats
There was no statistically significant difference in the 
number of crossed quadrants between the CEt and CNEt 
groups of rats (Table III). 
Single and chronic treatment (7 days) with ARI 
(1.5 mg/kg) administered to alcohol‑exposed animals 
showed a statistically significant improvement of spatial 
memory – decrease in the crossed quadrants compared to 
CEt control group of rats (p<0.05 vs. CEt) (Table III). 
Only after chronic treatment with FLU (5 mg/kg) (7 days) 
a statistically significant decrease in the crossed quadrants 
(memory improving) compared to the CEt control group 
of rats (p<0.05 vs. CEt) (Table III) was observed. There was 
no statistically significant difference compared to CNEt 
control group (Table III). 
After single and chronic administration of ARI+FLU to 
the alcohol‑exposed group of female rats, no statistically 
significant difference was observed in the number of 
crossed quadrants compared to CEt and CNEt groups of rats 
(Table III). 
DISCUSSION 
Studies on the effect of ethanol on human and animal 
locomotor activity yield ambiguous results (Eckardt et al. 
1998); some authors claim that, depending on the dose, 
alcohol has a sedative effect (Risinger et al. 1994), some 
that it has a stimulating effect (Wilson et al. 1998, Loftis 
et al. 2006). Because of the differences in ethyl alcohol 
metabolism between women and men (Frezza et al. 1990, 
Taylor et al. 1996) and higher concentration of ethyl alcohol 
in women’s blood (at the same dose), it was reasonable 
Table  III. Effects of single and chronic treatment with ARI and FLU and combined treatment with both drugs on memory measured in the MWM test 
(crossed quadrants) in alcohol‑exposed female rats
Group
Crossed quadrants
Friedman H[3.39]Single 
administration
(x±SEM)
Chronic treatment
7 days
(x±SEM)
14 days
(x±EM)
21 days
(x±SEM)
Saline (0.5 ml/rat)  
CONTROL NON‑ETHANOL 
(CNEt)
3.95±0.82 2.58±0.29 2.65±0.55 2.04±0.32 2.3
Saline (0.5 ml/rat)  
CONTROL ETHANOL  
(CEt)
4.41±0.51
NS vs. CNEt
3.88±0.49
NS vs. CNEt
3.53±0.43
NS vs. CNEt
3.08±0.39
NS vs. CNEt 2.7
ARI 1.5 mg/kg ip  
30 min before the test  
(CEt)
2.84±0.47*
p=0.0362
2.69±0.26*
p=0.0458
3.03±0.52
NS
2.45±0.31
NS 3.0
FLU 5 mg/kg po  
60 min before the test  
(CEt)
4.00±0.68
NS
2.64±0.24*
p=0.0355
2.65±0.47
NS
2.79±0.47
NS 2.8
ARI 1.5 mg/kg+FLU  
5 mg/kg (CEt)
3.26±0.50
NS
3.03±0.33
NS
2.70±0.47
NS
3.10±0.63
NS 1.9
Kruskal‑Wallis H [4.49] 9.6 10.1 2.3 2.0
Number of housed animals=10
* Statistically significant difference p<0.05 vs. CEt group
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to study the effect of aripiprazole and fluoxetine on 
ethyl alcohol’s effects, such as its effect on locomotor 
activity, in female animals. Currently, there are only a few 
references on ARI’s and FLU’s effect on locomotor activity 
(Richtand et al. 2012) and no research papers on combined 
administration of these two drugs to female rats exposed 
to ethyl alcohol. 
Our results have shown a statistically significant mobility 
increase on day 21 in the group of ethanol‑exposed females 
(CEt) compared to the non‑ethanol‑exposed group (CNEt). 
Similar results in females were obtained by Quintanilla 
(1999), indicating a statistically significant increase of 
female rats’ mobility after ethanol administration. Waller 
(1986) reached similar conclusions suggesting that the effect 
of locomotor stimulation in animals may depend on the 
alcohol dose used. Increased locomotor activity is typical for 
rats receiving ethanol in low doses (0.12–0.25 g/kg) (Waller 
et al. 1986, June and Lewis 1994). Other authors, have also 
shown a stimulative effect – increased locomotor activity for 
small doses of ethanol (2 g/kg) would explain its anxiolytic 
effect (Boerngen‑Lacerda and Souza‑Formigoni 2000). 
Upon ARI administration to ethanol‑exposed females, 
no statistically significant differences in animal mobility 
were found, either upon single or chronic administration. 
Similar results were obtained by Ingman and others 
(2006) who have shown that low doses of ARI (up to 3 mg) 
failed to affect locomotor activity. Burda and colleagues 
(2011), on the other hand, observed sedation upon 
chronic administration of ARI (for 14 days) at the dose 
of 6 mg/kg to male rats (Burda et al. 2011) which may be 
explained with minimal affinity of the drug to histaminic 
and α1‑adrenergic receptors (Muzina 2009). Clinical trials 
conducted in the United States by Owen and others (Owen 
et al. 2009) found only rare cases of sedation in patients 
receiving aripiprazole. These results corroborate with 
other clinical trials, e.g. by Kohen and colleagues (2010) 
and Muzina (2009). Therefore, it may be believed that no 
sedative effect is observed in ethanol‑exposed female rats. 
ARI administered at the dose of 1.5 mg/kg 30 min prior to 
the experiment to female rats failed to modify locomotor 
activity of alcohol‑exposed females. 
Chronic administration of FLU (21 days) caused 
a statistically significant reduction of the females’ mobility 
compared to the control group receiving ethanol (CEt). Our 
results corroborate with results of the study by Uzbay and 
others (2004) which also found a statistically significant 
reduction of mobility in females exposed to alcohol 
following FLU administration. Studies by Gobert and 
colleagues (1997) indicate that FLU administration causes 
DA level increase in the rats’ frontal cortex which may be 
the reason for the animals’ increased mobility (Gobert et 
al. 1997, Noorafshan et al. 2014). This is also confirmed in 
the study by Dyr (2001) who found this to be due to ethyl 
alcohol’s effect on striatal DA levels. 
Combined administration of ARI+FLU after 14 and 
21 days would cause a statistically significant reduction 
of the animals’ mobility compared to the control group 
receiving ethanol (CEt). It is possible that combined 
administration of Ari and FLU enhances the effect of these 
drugs on the serotoninergic and dopaminergic systems 
and blocks relevant receptors in the limbic system (CB1) 
and brain striatum (5‑HT2A/2C) (Dyr 2001, Uzbay et al. 
2004, Chun‑Fu et al. 1998, Pietrzak et al. 2011), hence the 
observed effect.
Studies by some authors suggest that chronic 
consumption of alcohol may impair cognitive functions, 
mainly operating memory and executive processes 
(NIAAA 2001).
Our studies on spatial memory in females show no 
statistically significant differences compared to the 
non‑ethanol‑exposed group (CNEt). This corroborates with 
reports of some authors who also failed to observe any 
statistically significant differences in this respect (Cacace 
et al. 2012). 
Our results show a spatial memory improvement 
in ethanol‑exposed rats both upon single and chronic 
administration of ARI (7×). No memory improvement was 
observed, however, after 14 or 21 days of ARI administration. 
Improvement of spatial memory in male rats upon single and 
chronic administration of ARI was also reported by Burda 
and others (2011). In rats receiving ethanol on a long‑term 
basis, Burda‑Malarz and colleagues (2014a) noticed a spatial 
memory improvement also upon single administration of 
ARI at the dose of 6 mg/kg. In ethyl alcohol‑preferring rats, 
Burda‑Malarz and others (2014b) observed that aripiprazole 
had no effect on memory at the dose of 6 mg/kg (no effect 
upon single or chronic administration) which may be due 
to changes in the dopaminergic and serotoninergic system 
induced by ethanol. Neither did Ratajczak and colleagues 
(Ratajczak et al. 2012) find any memory improvement upon 
administration of 1.5 mg/kg of ARI to alcohol‑exposed rats 
compared to the control group. 
FLU, likewise, improved spatial memory both upon 
single and chronic administration (7 and 14 days, but not 
21 days) which corroborates with our previous studies on 
male rats (Burda‑Malarz et al. 2014a, 2014b). This could 
be explained with FLU’s effect on neurogenetic processes 
in the hippocampus which is important in particular 
considering frequent damages of this brain structure in 
chronic alcohol consumers (Klomp et al. 2015). 
Combined administration of ARI+FLU improved 
memory in alcohol‑exposed females only upon single 
administration. Lack of effect upon chronic administration 
may be due to the tolerance to memory improvement 
developing upon combined administration of ARI+FLU. 
Semba and others (Semba et al. 1995) obtained similar 
results to support this hypothesis and found that high 
doses of FLU have an agonistic effect on D2 and D3 
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receptors located in the striatum, which may lead to 
spatial memory impairment. Preskorn (2003) also claimed 
that FLU limited 5‑HT reuptake, thus modifying ARI’s 
activity. In addition to this, chronic administration of 
FLU frequently led to saturation of DR receptors (located 
in the rats’ pituitary glands) (Inoue et al. 1998) and 
subcortical structures (Sesack and Carr 2002), agonistic 
effect on 5‑HT1A (in the new cortex) (Newman‑Tancredi 
et al. 1996), and antagonistic effect on 5‑HT2A receptors 
in the mesolimbic system (McGavin and Goa 2002), 
leading to the effect observed upon repeated combined 
administration of these drugs. 
CONCLUSION 
It can be concluded that ARI at the dose of 1.5 mg/kg, 
FLU at the dose of 5 mg/kg, and combined administration 
of these drugs improves spatial memory in female rats 
exposed to ethanol (which effect generally subsides upon 
chronic administration of these drugs). This may also be 
related to the alcohol’s effect on DA and 5‑HT systems in 
the brain. Due to the limited number of reports on the 
drugs’ modifying effect on memory in alcohol‑exposed 
female rats, further studies on this subject are necessary. 
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